A28 Therapeutics
A28 Therapeutics is a clinical-stage biopharmaceutical company developing targeted oncolytic peptides (TOPs) for treating cancer.
Last updated September 1, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
A28 Therapeutics is a privately-held, clinical-stage biopharmaceutical company founded in 2021, focused on developing its targeted oncolytic peptide platform for the treatment of multiple cancer types. Its lead compound, AT-101, has been clinically tested through a Phase 2a study and is being developed for indications including metastatic ovarian cancer with liver metastases and hepatocellular carcinoma.
History
A28 Therapeutics was founded in 2021 by Stanley Lewis, who serves as CEO. The company is a privately-held, clinical-stage biopharmaceutical company focused on developing its targeted oncolytic peptide platform for treating multiple cancer types. Its lead compound, AT-101, has been clinically tested through a Phase 2a study.
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/a28-therapeutics · Editorial policy · How profiles are compiled